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Abstract
AIM: To evaluate the clinical and biochemical profi le of 
patients with non alcoholic fatty liver disease (NAFLD) 
and to assess their histological severity at presentation. 
METHODS: Consecutive patients presenting to the liver 
clinic of All India Institute of Medical Sciences (AIIMS) 
with raised transaminases to at least 1.5 times upper 
limit of normal, and histologically confi rmed non-alcohol-
ic fatty liver disease were included. Patients who had sig-
nifi cant alcohol intake or positive markers of other liver 
diseases or who were taking drugs known to produce 
fatty liver were excluded. The clinical, biochemical and 
histological profi le of this group was studied. 
RESULTS: Fifty-one patients with NAFLD formed the 
study population. Their median age and BMI were 
34(17-58) years and 26.7(21.3-32.5) kg/m2 respectively 
and 46 (90.1%) were males. The majority of the patients 
had mild inflammation, either grade 1 [32 (63%)] or 
grade 2 [16 (31%)] and only 3 (6%) patients had severe 
(grade 3) infl ammation. Twenty-three (45%), 19 (37%), 
8(16%) and 1(2%) patient had stage 0, 1, 2 and 3 fi bro-
sis respectively on index biopsy and none had cirrhosis. 
On univariate analysis, triglyceride levels more than 150 
mg % (OR = 7.1; 95% CI: 1.6-31.5, P = 0.002) and AST/
ALT ratio > 1 (OR = 14.3; 95% CI: 1.4-678.5, P = 0.008) 
were associated with high grades of inflammation and 
none was associated with advanced fibrosis. On multi-
variate logistic regression analysis, hypertriglyceridemia 
>150 mg% was the only factor independently associated 
with presence of high grade of infl ammation (OR = 1.6; 
95% CI: 1.3-22.7, P  = 0.02), while none was associated 
with advanced fi brosis. Triglyceride levels correlated pos-
itively with infl ammatory grade (r = 0.412; P  = 0.003). 
CONCLUSION: NAFLD in North Indian patients is a 
disease of young over-weight males, most of whom are 
insulin resistant and they tend to have a mild histological 
disease at presentation. 
© 2006 The WJG Press. All rights reserved.
Key words: Infl ammation; Fibrosis; Triglycerides; Non al-
coholic steatohepatitis
Madan K, Batra Y, Gupta SD, Chander B, Anand Rajan 
KD, Tewatia MS, Panda SK, Acharya SK. Non-alcoholic 
fatty liver disease may not be a severe disease at pre-
sentation among Asian Indians. World J Gastroenterol 
2006; 12(21): 3400-3405
 http://www.wjgnet.com/1007-9327/12/3400.asp
INTRODUCTION
With the increasing awareness and early recognition of  as-
ymptomatic patients with raised transaminases and the on-
going epidemic of  the metabolic syndrome, non alcoholic 
fatty liver disease (NAFLD) has become a common cause of  
referral to hepatology clinics[1]. NAFLD can be divided into 4 
histological types (types 1 to 4)[2]. Studies from the west have 
demonstrated that NAFLD, especially NAFLD type 3 and 
4 can progress over a variable period, in 25%-40% patients, 
to cirrhosis and can contribute to liver-related mortality[2,3]. 
Recently there have been reports linking the development 
of  hepatocellular carcinoma to non alcoholic steatohepatitis 
(NASH)[4,5]. Studies from Europe and United States have 
demonstrated that up to 40% patients with NAFLD have 
advanced fi brosis and a proportion even have cirrhosis on the 
index biopsy[6,7].
The prevalence of  fatty liver in the general population of  
India has been shown to be as high as 24%[8], which is similar 
to that reported from some of  the western countries, where it 
parallels the prevalence of  obesity[9,10]. Despite the high preva-
lence of  NAFLD in India and rapidly rising incidence of  
type 2 diabetes mellitus in this country, data on hepatic mor-
phology, to indicate the severity of  NAFLD is limited[11-13]. 
The above-mentioned 3 studies reported demographic and 
biochemical profile of  patients with NAFLD. Histological 
parameters were studied in only a small number of  patients. 
By now it is clear that histological type 3 and 4 NAFLD are 
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associated with progressive liver disease and therefore needs 
therapeutic interventions. The present prospective study was 
designed to assess the magnitude of  advanced liver damage 
and fi brosis among consecutive patients with biopsy proven 
NAFLD.
MATERIALS AND METHODS
Study design
It is a cross sectional study to evaluate the clinical, biochemi-
cal and histological profile of  patients with NAFLD. The 
study was approved by the ethics committee of  the All India 
Institute of  Medical Sciences(AIIMS), New Delhi.
Patients
Inclusion criteria: Consecutive patients presenting to the 
liver clinic of  AIIMS, with raised transaminases to at least 
1.5 times upper limit of  normal, and histologically confi rmed 
NAFLD, were included.
Exclusion criteria: Patients in whom alcohol intake ex-
ceeded 20 grams per day (history of  alcohol intake was 
taken separately from the patients and the closest rela-
tives), patients with positive markers for other liver diseas-
es (hepatitis viruses A through E, autoimmune, Wilson’s 
disease, alpha 1 anti-trypsin defi ciency, hemochromatosis) 
and patients who were on medications known to induce 
fatty liver such as methotrexate, estrogens, amiodarone and 
tamoxifen were excluded.
Methods
All patients were evaluated with a thorough history and ex-
amination especially to exclude intake of  signifi cant amounts 
of  alcohol and to exclude intake of  potentially hepatotoxic 
drugs. Anthropometric measurements were taken at the initial 
visit. These included the weight, height, waist and hip circum-
ferences. Body mass index (BMI) and waist hip ratios were 
calculated as weight/height2. After an overnight fast, 10 mL 
of  blood was collected for a complete blood count and bio-
chemical investigations including a liver function profi le, lipid 
profi le, fasting serum insulin and fasting blood glucose. 
Hepatitis virus serologies included hepatitis B surface 
antigen (HBsAg), total antibodies to hepatitis B core antigen 
(total anti-HBc) and antibodies to hepatitis C virus (anti-
HCV). Anti-HCV was done using a sensitive commercial 
ELISA (Xcyton, Bangalore, India)[12] and the remaining viral 
serologies were done using commercial ELISA kits (Organon 
Teknika, Boxtel, The Netherlands). Serum ferritin and 24-h 
urinary copper estimation were done using conventional bio-
chemical techniques[13,14]. Alpha one anti-trypsin (α1AT) phe-
notyping was done using isoelectric focusing (PHAST system; 
Pharmacia Biotech, Uppsala, Sweden)[15]. The anti-nuclear 
antibodies (ANA), anti- smooth muscle antibodies (ASMA) 
and anti-liver kidney and microsomal antibodies (anti-LKM1) 
were carried out using the immunofluorescence technique. 
Hepatitis C virus RNA was detected using the polymerase 
chain reaction method as standardized at our laboratory[15] .
Liver biopsy was done after an informed consent in all 
patients suspected to have NAFLD, using an 18-gauge Meng-
hini’s aspiration needle. Each biopsy specimen, after being 
fi xed in 10% formalin, had routine hematoxylin-eosin stains 
and special stains such as reticulin, Masson’s trichrome, Perl’
s iron stain and Orcein stain for copper and periodic acid 
Schiff  after digestion with diastase. Immunoperoxidase stain-
ing to detect HBsAg and hepatitis B core antigen (HBcAg) 
was carried out in all patients to exclude the presence of  
chronic viral hepatitis. The classifi cation given by Brunt et al 
was used to grade and stage NASH[16].
An ultrasonography scan of  the upper abdomen was 
done in all patients in order to examine presence of  fatty liver 
and to exclude any obstructive biliary pathology or the pres-
ence of  any hepatic space occupying lesion.
Fasting serum insulin values were used along with si-
multaneous fasting blood glucose measurements to calculate 
HOMA-IR (homeostasis model assessment) according to the 
formula given below. 
HOMA-IR = (fasting serum insulin (μIU/mL)×fasting plas-
ma glucose (mg%))/(22.5 ×18)
Value of  HOMA-IR more than 1.64 implied the pres-
ence of  abnormally high insulin resistance[17].
Defi nitions
Diabetes was regarded to be present if  the fasting venous 
plasma glucose was more than 126 mg%[18] . Patients with 
BMI of  more than 23 were seen to be overweight and those 
with a BMI of  >25 were labeled as obese (Asian standards)[19]. 
Hypertriglyceridemia was defi ned as a fasting serum triglyc-
eride level of  more than 150 mg%. Patients who had at least 
three of  the following fi ve components: hyperglycemia (fasting 
blood sugar >110 mg% or known type 2 diabetes mellitus, 
central obesity (as defi ned by a higher waist-hip ratio), hyper-
tension, hypertriglyceridemia (serum triglyceride > 150 mg%), 
and low HDL cholesterol levels (< 50 for women and < 40 
for men), were labeled to have the metabolic syndrome. Since 
we did not have waist hip ratio in a large number of  patients, 
we used obesity (BMI > 25 kg/m2) as a surrogate for high 
waist hip ratio, as one of  the component of  the metabolic 
syndrome[20,21].
Statistical analysis
The results were expressed as median (range) for continu-
ous variables and as frequencies (proportions) for categori-
cal variables. Factors suspected to influence the severity of  
grade and stage were tested in a univariate and multivariate 
logistic regression analysis. For the univariate and multivari-
ate analyses, the dependent variable was the presence of  mild 
infl ammation (grades 0, 1) or severe infl ammation (grades 2, 
3) for assessing the association with infl ammatory grade and 
mild fi brosis (stages 0, 1) or severe fi brosis (stages 2, 3, 4) for 
assessing association with fibrosis stage. The independent 
variables were age>35, sex, BMI > 25 kg/m2, AST/ALT ratio 
>1, cholesterol >200 mg%, triglycerides >150 mg%, HOMA-
IR >1.64, presence or absence of  hypertension and metabolic 
syndrome. Correlation between histological severity and the 
above mentioned independent variables was carried out using 
Spearman’s correlation. For skewed data, non-parametric tests 
were used wherever necessary. All data were analyzed using 
the SAS 8.0 statistical package.
RESULTS
From January 1999 to June 2005, 51 patients with histologi-
cally proven NAFLD were registered at the liver clinic of  
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AIIMS. This number formed 2.6% of  all liver clinic referrals 
during this time period.
The median age of  this cohort of  patients was 34 
(17-58) years, the BMI was 26.7 (21.3-32.5) kg/m2 and 
46 (90.1%) were males. Median AST/ALT ratio was 0.63 
(0.31-2.61). Table 1 gives the baseline demographic and bio-
chemical profi le of  the patients.
Prevalence of features of metabolic syndrome
Table 2 depicts the prevalence of  individual features of  the 
metabolic syndrome in these patients. Eighty percent patients 
had high HOMA-IR, while 69.4%, 40.8%, 36.4%, 11.8% and 
10% had obesity, hypertriglyceridemia, low HDL cholesterol, 
hypertension and diabetes respectively. All the investigations 
and clinical features required for diagnosing the metabolic 
syndrome were available in 43 patients. Of  these, 9(20.9%) 
patients fulfi lled the criteria for a diagnosis of  metabolic syn-
drome (presence of  3 or more components of  the metabolic 
syndrome).
Histological severity and factors associated with severe 
disease
Twenty-eight (55%) patients had NASH (type 3 or 4 
NAFLD) whereas the rest had only fatty liver with or without 
spotty necrosis without evidence of  either necrosis or fi brosis 
(type 1 or 2 NAFLD).
Infl ammatory grade: The majority of  the patients had mild 
infl ammation, either grade 1 [32 (63%)] or grade 2 [16 (31%)]. 
Only 3(6%) patients had severe or grade 3 infl ammation.
We evaluated factors which could have been associated 
with moderate to severe infl ammation (grade 2 or 3) versus 
those with mild inflammation (grade 0 or 1). On univariate 
analysis, triglyceride levels more than 150 mg % (OR = 7.1; 
95% CI: 1.6-31.5, P = 0.002) and AST/ALT ratio > 1 (OR = 
14.3; 95% CI: 1.4-678.5, P = 0.008) were signifi cantly associ-
ated with high grades of  inflammation. Presence of  meta-
bolic syndrome was more common among patients who had 
severe infl ammation although it did not reach the signifi cant 
value (Table 3). On multivariate logistic regression analysis, 
hypertriglyceridemia more than 150 mg% was the only fac-
tor independently associated with presence of  high grade of  
infl ammation on index biopsy (OR = 1.6; 95% CI: 1.3-22.7, 
P = 0.02). There was also positive correlation between the tri-
glyceride levels and infl ammatory grade (r = 0.412; P = 0.003) 
(Figure 1)
Fibrosis stage: Most of  the patients had either no or mini-
mal fi brosis. Twenty-three (45%) and 19 (37%) patients had 
stage 0 and stage 1 fi brosis respectively on liver biopsy. Eight 
(16%) had stage 2 and 1 (2%) had stage 3 fibrosis. No pa-
tient had cirrhosis on index biopsy. On evaluation of  factors, 
which could have been associated with severe fi brosis (stages 
2, 3, 4 versus stages 0,1), metabolic syndrome (OR = 5.6; 95% 
CI: 0.7-36.5, P = 0.04) and  AST/ALT ratio > 1 (P = 0.09) 
were more commonly present among patients with advanced 
fi brosis but failed to reach signifi cance (Table 4).
DISCUSSION
Although NAFLD has been demonstrated to be present in 
almost one quarter of  the general population[10] and has been 
Table 1  Baseline demographic and 
biochemical parameters of the cohort
Parameters Value
Age (yr)
n
Median
(Range)
51
34
(16-58)
Sex ratio (males/females) 46/5
Body mass index (kg/m2)
n
Median
(Range)
49
   26.7
(21.3-32.5)
Bilirubin (mg%)
n
Median
(Range)
51
     0.8
(0.5-13.0)
Aspartate aminotransferase (IU/L)
n
Median
(Range)
51
66
(29-230)
Alanine aminotransferase (IU/L)
n
Median
(Range)
51
98
(52-349)
Alkaline phosphatase (IU/L)
n
Median
(Range)
  51
159
(87-372)
Albumin (gm%)
n
Median
(Range)
47
    4.6
(3-5.4)
Cholesterol (mg%)
n
Median
(Range)
  49
180
(96-323)
Triglycerides (mg%)
n
Median
(Range)
 49
145
(48-339)
HDL cholesterol (mg%)
n
Median
(Range)
44
41
(28-65)
Fasting plasma glucose (mg%)
n
Median
(Range)
49
90
(70-150)
Fasting serum insulin (μIU/L)
n
Median
(Range)
45
   10.4
(1.6-28.4)
HOMA-IR 
n
Median
(Range)
45
    2.4
(0.3-6.0)
HDL: High density lipoprotein, HOMA-IR: 
Homeostasis model assessment for insulin 
resistance.
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scribed classically from the west. This difference would not 
be surprising, considering the fact that the body fat distribu-
tion and risk of  cardiovascular complications with similar 
amount of  body fat differs between Asian Indians and their 
western counterparts. This has even prompted lowering of  
BMI and waist-hip ratio cut-offs for defi ning overweight and 
obesity among Asians[24,25]. Since obesity and fat distribution 
are integral parts of  the insulin resistance syndrome and fatty 
liver forms part of  the spectrum of  abnormalities associated 
with this syndrome, the difference in the baseline profi les of  
NAFLD patients would be obvious.
The mean age of  presentation of  our patients, most of  
whom were detected during workup of  asymptomatic transa-
minitis was about a decade younger than the western patients. 
The younger age of  presentation may suggest increasing 
health awareness among our population with lower thresholds 
for health check-ups during which the asymptomatic transa-
minitis is picked up and investigated. It may also suggest the 
shown to be responsible for one third of  patients with as-
ymptomatic transaminitis in India, little is known about the 
baseline clinical, biochemical and histological profi le of  these 
patients. The present study described the baseline profi le in 
North Indian patients with biopsy proven NAFLD.
Our study demonstrated NAFLD to be a disease of  
younger age group with a mean age at presentation being 33.3 
(8.01) years. More than 90% of  the patients were males. This 
predilection for involvement of  males has been seen not only 
in other studies from Northern India[13-15] , but also in the 
United States[22]. This is different from what used to be the 
classical phenotype of  NASH patients, where it was described 
to be a disease of  middle-aged females. The reason for this 
male preponderance has been described as a higher waist-
hip ratio in men as compared to women, an indicator of  
central obesity and insulin resistance. Twenty-one percent of  
our patients with NAFLD were found to have the metabolic 
syndrome. The prevalence rate of  metabolic syndrome in the 
general population of  India has been reported to be approxi-
mately 8% in men older than 20 years[23], but no study has 
earlier reported the prevalence of  the metabolic syndrome in 
patients with NAFLD from India.
The present study also highlights certain important dif-
ferences between the phenotype of  the cohort of  NAFLD 
as seen in Northern India versus that which has been de-
Table 2  Prevalence of indiv idual 
components of metabolic syndrome
Component of metabolic syndrome n  (%)
Obesity 34 (69.4)
Hypertriglyceridemia 20 (40.8)
Low HDL cholesterol 16 (36.4)
High HOMA-IR 36 (80)
Hypertension  6 (11.8)
Diabetes   5 (9.8)
Metabolic syndrome  9 (20.9)
HDL: high density lipoprotein; HOMA-IR: 
Homeostasis model assessment for insulin 
resistance.
BMI: body mass index; AST: Aspartate aminotransferase; ALT: 
Alanine aminotransferase; HOMA-IR: homeostasis model assessment 
for insulin resistance; Univariate analyses; P value on chi-square or 
Fisher’s exact test.
Table 3  Factors associated with advanced grade of 
infl ammation 
Variables
Grade 0/1
(n/N)
Grade 2/3 
(n/N)
P
Male 29/32 17/19 1.0
Age >35 years 13/32 10/19   0.40
BMI >25 kg/m2 18/30 16/19   0.11
AST/ALT ratio > 1  1/32  6/19     0.008
Cholesterol > 200 mg%  9/30  5/19 1.0
Triglycerides >150 mg%  7/30 13/19     0.002
HOMA-IR >1.64 21/26 15/19 1.0
Hypertension  4/32  2/19 1.0
Metabolic syndrome  3/30  6/19   0.07
Table 4  Factors associated with advanced stage of fi brosis
Variables
Stage 0/1
(n/N)
Stage 2/3/4
(n/N)
P
Male sex  4/42 1/9 1.0
Age >35 years 17/42 6/9 0.26
BMI >25 kg/m2 26/42 8/9 0.24
AST/ALT ratio > 1  4/42 3/9 0.09
Cholesterol > 200 mg% 13/40 1/9 0.41
Triglycerides >150 mg% 14/40 6/9 0.13
HOMA-IR >1.64 28/36 8/9 0.66
Hypertension   5/42 1/9 1.0
Metabolic syndrome   5/40 4/9 0.04
BMI: body mass index; AST: Aspartate aminotransferase; ALT: Alanine 
aminotransferase; HOMA-IR: Homeostasis Model assessment for insulin 
resistance; Univariate analyses; P value on chi-square and fi sher’s exact 
test.
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Figure 1  Scatter plot demonstrating positive correlation between triglyceride 
levels and infl ammatory grade. [Coeffi cient of correlation (r) = 0.412; P = 0.003 
using spearman’s correlation].
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is available in these patients. Another factor which could be 
responsible for milder disease in these patients is the lower 
BMI. But this may not be true, because as has been discussed 
earlier, Asians with lower BMI may also be predisposed to 
similar risk of  developing the metabolic syndrome as Cauca-
sians with higher BMI. Further the effect of  BMI or age was 
not seen on the degree of  fi brosis in the univariate analysis. 
No other factor was found to be associated with severe fi bro-
sis in the present study. The lack of  association might be due 
to small number of  patients in the group of  severe fi brosis, 
as only a minority of  patients had advanced fi brosis. Studies 
from the west, however have reported higher BMI, older age, 
type 2 diabetes mellitus, AST/ALT ratio > 1 and hypertri-
glyceridemia to be independent risk factors for presence of  
advanced fi brosis on index biopsy[8,9]. The milder histological 
disease in the present cohort may also represent a genetic 
predisposition in our patients, just like their genetic predispo-
sition to develop metabolic syndrome. Whether these patients 
with mild fibrosis continue to have a mild disease or they 
progress to a stage of  cirrhosis can only be answered once we 
have an adequate follow up on them.
To conclude, NAFLD in North Indian patients is a 
disease of  young overweight males, most of  whom are 
insulin resistant and they tend to have a mild histological 
disease at presentation.
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